Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis.
Posaconazole (PCZ) is approved for fungal prophylaxis in high-risk neutropenic patients. Unfortunately, PCZ oral absorption is affected by nutritional intake and drug interactions with proton pump inhibitors (PPIs) and possibly histamine-2 antagonists (H2As). Cancer patients frequently receive stress ulcer prophylaxis (SUP) with PPIs or H2As. Recommended PCZ steady-state concentrations (C(ss)) are difficult to achieve using the traditional dosing regimen of 200 mg thrice daily. Given the paucity of guidance on PCZ dosing in patients receiving SUP, this study evaluated attainment of targeted PCZ C(ss) (0.5 μg/mL and 0.7 μg/mL) with two different PCZ dosing regimens when SUP was given. Twenty patients received the traditional dosing and 34 patients received 400 mg twice daily. Median PCZ C(ss) levels were 0.37 μg/mL and 0.32 μg/mL with the traditional and 400 mg twice-daily regimens, respectively (P=0.809). When stratified by type of SUP, H2A patients had a median PCZ C(ss) of 0.39 μg/mL, whereas PPI patients had a median PCZ C(ss) of 0.32 μg/mL. Despite having more patients with PCZ C(ss) >0.5 μg/mL in the H2A group, a statistical significance was not found (P=0.368). Multiple logistic regression did show that increasing age [odds ratio (OR)=1.08, 95% confidence interval (CI) 1.03-1.19] and use of H2As over PPIs (OR=6.8, 95% CI 1.22-55.16] was associated with PCZ target attainment. These results suggest that PCZ target attainment is similar with either PCZ regimen but that there may be less of an interaction with H2As compared with PPIs.
Department of Pharmacy Services, West Virginia University Healthcare, Morgantown, WV, USA.
Ashley L
AL
Ross
Douglas
D
Slain
Aaron
A
Cumpston
Alexander M
AM
Bryant
Mehdi
M
Hamadani
Michael
M
Craig
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018890:Chemoprevention / Q000379:methods*; D004347:Drug Interactions; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000517:prevention & control*; D010949:Plasma / Q000737:chemistry; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D013312:Stress, Physiological; D014230:Triazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D014456:Ulcer / Q000517:prevention & control
D000935:Antifungal Agents; D054328:Proton Pump Inhibitors; D014230:Triazoles; C101425:posaconazole